Comparison of [ 18 F]DCFPyL and [ 18 F]FAPI-74 PET/CT imaging in metastatic prostate cancer.

Eur J Nucl Med Mol ImagingJun 26, 2026 (epub)
Clinical ResearchNuclear MedicineOncology (Medical)Open access

Anniina Hyväkkä, Marko Seppänen, Maria Sundvall et al.

✦ AI-curated · Sources linked

In 30 seconds

This prospective clinical trial compared the efficacy of PSMA-targeted [18F]DCFPyL and FAPI-targeted [18F]FAPI-74 PET/CT imaging in 39 patients with metastatic prostate cancer. The study found that [18F]DCFPyL detected 99% of lesions, while [18F]FAPI-74 identified only 58%. The median SUVmax was significantly higher for PSMA at 24 compared to FAPI at 5.4 (p < 0.001).

Key findings

  • [18F]DCFPyL detected 1351 lesions (99%) compared to [18F]FAPI-74's 788 lesions (58%).
  • Median SUVmax was 24 for PSMA and 5.4 for FAPI (p < 0.001).
  • Median tracer-positive tumor volume was 85 mL for [18F]DCFPyL and 10 mL for [18F]FAPI-74 (p < 0.001).
  • Only 14 lesions (1%) were FAPI-positive and PSMA-negative.

Why it matters

The study highlights the superior performance of PSMA PET/CT over FAPI PET/CT in detecting metastatic lesions in prostate cancer, which is crucial for guiding treatment decisions and optimizing patient management.

Source

PubMed · PMID 42350616Free full text on PubMed Central

Published in Eur J Nucl Med Mol Imaging. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nuclear Medicine

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.